Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 8, 2013, Pages 810-818

  Mack, Christina Defilippo ^a   Glynn, Robert J ^b   Brookhart, M Alan ^a   Carpenter, William R ^a,c   Meyer, Anne Marie ^c   Sandler, Robert S ^d   Stürmer, Til ^a  

^a University of North Carolina at Chapel Hill   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Colon cancer; Comparative effectiveness research; Epidemiologic methods; Oxaliplatin; Pharmacoepidemiology; Propensity scores

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

AGED; AGING; ARTICLE; CALENDAR TIME SPECIFIC PROPENSITY SCORE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; COLON CANCER; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CONFOUNDING VARIABLE; DRUG CHOICE; DRUG UTILIZATION; FEMALE; HAZARD RATIO; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRESCRIPTION; PRIORITY JOURNAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

COLON CANCER; COMPARATIVE EFFECTIVENESS RESEARCH; EPIDEMIOLOGIC METHODS; OXALIPLATIN; PHARMACOEPIDEMIOLOGY; PROPENSITY SCORES;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; COMPARATIVE EFFECTIVENESS RESEARCH; FEMALE; FLUOROURACIL; HUMANS; LOGISTIC MODELS; MALE; MEDICARE; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; TIME FACTORS; UNITED STATES;

EID: 84880724782     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3386     Document Type: Article

References (44)

1. Rosenbaum PR, Rubin DB. The Central Role of the Propensity Score in Observational Studies for Causal Effects. Biometrika 1983; 70: 41-55.
2. Stürmer T, Schneeweiss S, Brookhart MA, Rothman KJ, Avorn J, Glynn RJ. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol 2005; 161(9): 891-8.
3. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 757-763.
4. National Cancer Institute. Highlights from ASCO 2003. May 31, 2003. http://www.cancer.gov/asco2003/highlights [30 October 2010].
5. André T, Boni C, Mounedji-Boudiaf L, et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-51.
6. National Cancer Institute. FDA Approval for Oxaliplatin. http://www.cancer.gov/cancertopics/druginfo/fda-oxaliplatin [27 December 2012].
7. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002; 40(8 Suppl): IV-3-18.
8. National Cancer Institute. SEER Program Overview. http://seer.cancer.gov/ [24 Sept 2010].
9. Glymour MM, Greenland S. Causal Diagrams. In Modern epidemiology (3rd edn), Rothman KJ, Greenland S, Lash TL (eds). Philadelphia, PA: Lippincott Williams & Wilkins, 2008; pp. 183-194.
10. Sanoff HK, Carpenter WR, Martin CF, et al. Comparative Effectiveness of Oxaliplatin vs Non-Oxaliplatin-containing Adjuvant Chemotherapy for Stage III Colon Cancer. J Natl Cancer Inst 2012; 104(3): 211-27. Epub 2012 Jan 20.
11. Parsons LS. Reducing bias in a propensity score matched pair sample using greedy matching techniques. Proceedings of the 26th annual SAS users group international conference, Cary, NC. http://www2.sas.com/proceedings/sugi26/p214-26.pdf.
12. Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006; 59: 437-47.
13. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1(11): 710-9.
14. Seeger JD, Walker AM, Williams PL, Saperia GM, Sacks FM. A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. Am J Cardiol 2003; 92: 1447-1451.
15. Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf 2005; 14: 465-476. Doi: 10.1002/pds.1062.
16. Rassen JA, Glynn RJ, Rothman KJ, Setoguchi S, Schneeweiss S. Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. Pharmacoepidemiol Drug Saf 2012; 21(7): 697-709. Doi: 10.1002/pds.2256. Epub 2011 Dec 8.
17. Mack CD, Glynn RJ, Stürmer T. Calendar Time-Specific Propensity Scores and Hazard Ratio Estimation. Pharmacoepidemiol Drug Saf 2011; 20(suppl 1): S296; Oral presentation, 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Chicago, IL, 2011.
18. Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther 2011; 90(6): 777-90. Doi: 10.1038/clpt.2011.235. Epub 2011 Nov 2.
19. Gagne JJ, Glynn RJ, Rassen JA, et al. Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system. Clin Pharmacol Ther 2012; 92(1): 80-6. Doi: 10.1038/clpt.2011.369. Epub 2012 May 16.
20. Burakgazi AZ, Messersmith W, Vaidya D, Hauer P, Hoke A, Polydefkis M. Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology 2011; 77(10): 980-6. Epub 2011 Aug 24.
21. Weickhardt A, Wells K, Messersmith W. Oxaliplatin-induced neuropathy in colorectal cancer. J Oncol 2011; 2011: 201593. Epub 2011 Dec 12.
22. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43(4): 817-24.
23. Ramanathan RK, André T, Rothenberg ML, et al. Diabetes mellitus (DM) and the incidence and time to onset of oxaliplatin induced peripheral sensory neurotoxicity (PSN) in patients with colorectal cancer. A pooled analysis of 3 randomized studies. American Society of Clinical Oncology. 2008 Gastrointestinal Cancers Symposium. Abstract 347. http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10742 [9 May 2012].
24. Haas JS, Brawarsky P, Iyer A, Fitzmaurice GM, Neville BA, Earle C. Association of area sociodemographic characteristics and capacity for treatment with disparities in colorectal cancer care and mortality. Cancer 2011; 117(18): 4267-76. Doi: 10.1002/cncr.26034. Epub 2011 Mar 16.
25. André T, Boni C, Navarro M, et al. Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial. J Clin Oncol 2009; 27(19): 3109-3116.
26. Sanoff HK, Carpenter WR, Martin CF, et al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst 2012; 104(3): 211-27. Epub 2012 Jan 20.
27. Schneeweiss S, Patrick AR, Stürmer T, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. MedCare 2007; 45(10 Supl 2): S131-42.
28. Mack CD, Carpenter W, Meyer AM, Sanoff H, Stürmer T. Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults. Cancer 2012; 118(11): 2925-34. Doi: 10.1002/cncr.26622. Epub 2011 Nov 9.
29. Stürmer T, Rothman KJ, Avorn J, Glynn RJ. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. Am J Epidemiol 2010; 172(7): 843-54. Epub 2010 Aug 17.
30. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. Am J Epidemiol 2006; 163(12): 1149-56. Epub 2006 Apr 19.
31. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 2007; 26(4): 734-53.
32. Rassen JA, Doherty M, Huang W, Schneeweiss S. Pharmacoepidemiology Toolbox. Boston, MA. http://www.hdpharmacoepi.org [25 July 2012].
33. Mack CD, Brookhart MA, Glynn RJ, Stürmer T. Calendar Time as an Instrumental Variable in Nonexperimental Comparative Effectiveness Research of Dynamic Therapies. Am J Epidemiol 2012; 175(suppl 11): 181-S; Oral presentation, 45th Annual meeting Society for Epidemiologic Research, Minneapolis, USA. 2012.
34. Cain LE, Cole SR, Greenland S, et al. Effect of highly active antiretroviral therapy on incident AIDS using calendar period as an instrumental variable. Am J Epidemiol 2009; 169(9): 1124-32. Epub 2009 Mar 24.
35. Johnston KM, Gustafson P, Levy AR, et al. Use of instrumental variables in the analysis of generalized linear models in the presence of unmeasured confounding with applications to epidemiological research. Stat Med 2008;27: 1539-1556.
36. Brookhart MA, Stürmer T, Glynn RJ, Rassen J, Schneeweiss S. Confounding control in healthcare database research: challenges and potential approaches. Med Care 2010; 48(6 Suppl): S114-20.
37. Bugeja G, Kumar A, Banerjee AK. Exclusion of elderly people from clinical research: a descriptive study of published reports. Br Med J 1997; 315(7115): 1059.
38. Sanoff HK, Carpenter WR, Freburger J, et al. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: A Population-based analysis. Cancer 2012. Doi: 10.1002/cncr.27422. [Epub ahead of print]
39. Abraham A, Habermann EB, Rothenberger DA, et al. Adjuvant chemotherapy for stage III colon cancer in the oldest old: Results beyond clinical guidelines. Cancer 2012. Doi: 10.1002/cncr.27755. [Epub ahead of print]
40. Altekruse SF, Kosary CL, Krapcho M, et al. (eds) SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, 2010, http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site [20 Mar 2010].
41. André T, Boni C, Mounedji-Boudiaf L, et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-51.
42. Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. Med Care 2002; 40: IV-43-8.
43. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 2002; 40: IV-55-61.
44. Glynn RJ, Knight EL, Levin R, Avorn J. Paradoxical relations of drug treatment with mortality in older persons. Epidemiology 2001; 12(6): 682-9.